Log in | Join Free | china | japan | germany

N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate

Request For Quotation
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate Suppliers list
Company Name: Lynnchem  
Tel: 86-(0)29-85992781 17792393971
Email: info@lynnchem.com
Products Intro: Product Name:N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate
CAS:960055-68-9
Purity:98% Package:1mg;10mg
Company Name: Novachemistry  
Tel: 44-20819178-90 02081917890
Email: info@novachemistry.com
Products Intro: Product Name:Panobinostat Lactate
CAS:960055-68-9
Purity:98% Package:1mg;10mg
Company Name: MSN LABORATORIES PRIVATE LTD  
Tel: +91 40 30438600
Email: info@msnlabs.com
Products Intro: Product Name:PANOBINOSTAT LACTATE
CAS:960055-68-9
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate Basic information
Product Name:N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate
Synonyms:Panobinostat Lactate;N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate
CAS:960055-68-9
MF:C24H29N3O5
MW:439.51
EINECS:
Product Categories:
Mol File:960055-68-9.mol
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate Structure
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate Chemical Properties
Safety Information
MSDS Information
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate Usage And Synthesis
DescriptionPanobinostat lactate is a histone deacetylase (HDAC) inhibitor that was approved by the FDA for the treatment of multiple myeloma. It was also approved for the same indication in Japan, and the EU approved its use in combination with bortezomib and dexamethasone for the treatment of adults with relapsed and/or refractory multiple myeloma. Panobinostat was discovered and developed by Novartis and is currently being investigated for a number of hematological cancers as well as other indications.
SynthesisGrandberg synthesis of 2-methyltryptamine (223) was accomplished in 47% yield by heating phenylhydrazine (221) with 5-chloro-2-pentanone (222). Reductive amination of 223 with (E)-3-(4-formyl-phenyl)-acrylic acid methyl ester (224) and sodium borohydride followed by formation of the hydrochloride salt provided amine hydrochloride 225 in high purity. Saponification of the methyl ester followed by reaction with hydroxylamine provided panobinostat in high overall yield. The free base was treated with racemic lactic acid and recrystallized in water to give panobinostat lactate (XXVIII).

Synthesis_960055-68-9

N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate Preparation Products And Raw materials
Tag:N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide DL-lactate monohydrate(960055-68-9) Related Product Information